Fig. 6.

Anti-CD8 mAb promotes susceptibility to proliferation in tolerant antigen-specific CD4⁺ T cells. BALB/c mice were treated with either, OVA plus the anti-CD4/anti-CD8 mAb cocktail, or OVA and anti-CD4 mAb plus isotype control, or with OVA alone. On day 42 after OVA and mAb treatment mice from each group were boosted with or without OVA. Three mice from each of the boosted groups and three from each of the non-boosted groups were fed BrdU either on days 0–3, or on days 3–6. Mice that were fed BrdU on days 0–3 were sacrificed on day 3, while those that were fed BrdU on days 3–6 were sacrificed on day 6 post-boosting. The splenocytes were isolated and the total number of CD4⁺KJ1-26⁺cells that were BrdU⁺ were determined by FACS. Data generated from the non-boosted mice fed BrdU on days 0–3 and 3–6 has been pooled and is indicated in the figure as no boost (n = 6). Data shown in each case are mean ± SEM and are representative of 2 experiments. * indicates statistical significance to 0.01–0.05. ** indicates statistical significance to 0.001–0.009. *** indicates statistical significance to 0.0001–0.0009. The Student t test was used to determine statistical significance. n = 3 per group.